Financial Data and Key Metrics Changes - For Q4 2025, R&D expenses were $14.6 million, up from $7.3 million in Q4 2024, primarily due to DRAGON II trial expenses and lower Australian R&D tax incentives [6][8] - SG&A expenses increased to $13.5 million from $4.2 million in Q4 2024, driven by higher share-based compensation and professional service fees [8][10] - The net loss for Q4 2025 was $25.3 million, compared to $10.1 million in Q4 2024, while the non-GAAP net loss was $13.6 million, up from $5.9 million in Q4 2024 [8][9] - For the full year, R&D expenses totaled $45.4 million, compared to $29.9 million in 2024, and SG&A expenses were $38.9 million, up from $10.1 million in 2024 [9][10] - The full year net loss was $77.6 million, compared to $36.1 million in 2024, with a non-GAAP net loss of $38.7 million, up from $27.2 million in 2024 [10][11] Business Line Data and Key Metrics Changes - The company achieved significant milestones in 2025, including the successful phase 3 DRAGON trial, which demonstrated a 36% reduction in the growth rate of atrophy lesions compared to placebo [4][5] - Enrollment in the DRAGON II study reached 72 subjects, with expectations to finalize between 72 and 75 subjects [4] - The phase 3 PHOENIX trial in GA completed enrollment with 430 subjects [5] Market Data and Key Metrics Changes - The company closed the year with $772.6 million in cash equivalents, significantly up from $145.2 million at the end of 2024, positioning it well for future objectives [11] Company Strategy and Development Direction - The primary focus for 2026 is the planned NDA submission to the FDA in Q2 2026, with commercialization preparations for Stargardt disease already underway [5][6] - The company aims to build its organization in sales, market access, medical affairs, marketing, regulatory, and operations [6] - The company is prioritizing the U.S. market for regulatory submissions, with plans to follow up with EMA and other regions post-U.S. approval [33][59] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the upcoming year, highlighting the transformative potential of Tinlarebant as a treatment for Stargardt disease [3][5] - The management noted that the absence of existing treatments for Stargardt disease could facilitate a straightforward launch process [27] - The company anticipates launching by Q1 2027, with a focus on genetic testing and patient awareness as key factors for success [26][27] Other Important Information - The company completed a $402 million public offering in Q4 2025, which supports its commercialization and pipeline development efforts [5] - Management indicated that pricing for the drug is still under consideration, with expectations that it could exceed the average rare disease drug price of approximately $350,000 [19] Q&A Session Summary Question: NDA submission process and cash usage - The NDA will be a rolling submission, with DRAGON II data relevant only for Japan. The company expects to spend about $150 million on R&D activities and $150-$200 million on commercialization over the next three years [14][15] Question: Pricing guidance and NDA gating items - Pricing is still being determined, but the company expects to set a price higher than the average for rare disease drugs. The key gating item before NDA submission is the finalization of the clinical study report [19][21] Question: Launch timing and challenges - The company expects to launch by Q1 2027, with a sales team focused on genetic testing and brand awareness. Challenges include patient and physician awareness of the treatment [26][27] Question: Ex-U.S. regulatory strategy - The company prioritizes the U.S. FDA submission, with plans to follow up with EMA and other regions after securing U.S. approval [33][59] Question: Stargardt disease prevalence and awareness - The company estimates about 53,000 patients in the U.S. are affected by Stargardt disease, and having a treatment available is expected to increase awareness and diagnosis of undiagnosed patients [64][66] Question: Pediatric studies - The company has an approved pediatric investigational plan with EMA to study safety and efficacy in children aged 3 to 11, with plans to expand into the pediatric population [68][70]